Litigation Details for Takeda Pharmaceutical Co v. Impax Laboratories, Inc. (Fed. Cir. 2013)

Takeda Pharmaceutical Co v. Impax Laboratories, Inc. (Fed. Cir. 2013)

Docket		Date Filed	2013-11-19
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	6,228,398; 7,790,755
Link to Docket	External link to docket

Details for Takeda Pharmaceutical Co v. Impax Laboratories, Inc. (Fed. Cir. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-11-19				External link to document

Litigation summary and analysis for: Takeda Pharmaceutical Co v. Impax Laboratories, Inc. (Fed. Cir. 2013)

Last updated: July 26, 2026

Takeda v. Impax Laboratories Inc. 14-1107: Litigation Summary, Patent-Claim Focus, and Business Impact

Executive summary: Takeda Pharmaceutical Co. v. Impax Laboratories, Inc., No. 14-1107, is a US patent dispute tied to Takeda’s branded product and Impax’s proposed generic. The matter turns on whether Impax’s “generic” ANDA product infringes Takeda-listed patents and whether the claims at issue are valid. Without the specific district court record, the asserted patents, and the appellate disposition, a complete claim-by-claim infringement and invalidity analysis cannot be produced to a litigation-grade standard.

What is Takeda Pharmaceutical Co v. Impax Laboratories, Inc. 14-1107 about?

Featured answer: The case is an infringement and validity dispute between Takeda and Impax in the generic-ANDA setting, heard in the Federal Circuit under case number 14-1107.

What usually drives a Takeda v. Impax ANDA appeal

In ANDA-related patent appeals, the litigation typically centers on:

• Claim construction for the asserted patent claims
• Infringement of the proposed generic formulation and/or method-of-use
• Validity arguments (anticipation, obviousness, enablement, written description)
• Standing and procedural posture issues (timing, scope of appeal)

What is missing for a complete 14-1107 litigation narrative

A litigation-grade summary requires:

• the district court (and its case number),
• the asserted patent numbers,
• what the Federal Circuit decided (affirmed/reversed, which claims),
• whether the appeal concerns infringement, validity, or both, and
• the mandate date and practical launch consequences.

Which patents were asserted in Takeda v. Impax 14-1107?

A complete answer must list:

• asserted US patent numbers,
• title and priority basis,
• claim numbers at issue, and
• whether the asserted patents were Orange Book-listed for the relevant FDA application.

Result: Not enough case-specific data is provided to enumerate the asserted patents accurately.

Claim types to map once patents are identified

Once the asserted patents are known, the analysis should split into:

• Composition/formulation patents (excipients, particle size, polymorphs, amorphous forms)
• Method-of-use patents (dosage regimens, timing, patient subpopulations)
• Manufacturing/process patents (steps controlling critical parameters)

What did the Federal Circuit decide in Takeda v. Impax 14-1107?

A complete litigation summary requires the holding:

• Appellate outcome: affirmed, reversed, vacated, remanded
• Scope: which claims/patents were dispositive
• Reasoning: claim construction errors, evidentiary sufficiency, legal standards applied

Result: The required disposition text is not included, so an accurate decision summary cannot be produced.

Typical decision structures in ANDA appeals

Federal Circuit opinions in Hatch-Waxman cases often include:

• claim construction section
• infringement section (literal infringement and/or doctrine of equivalents, depending on framing)
• validity section (anticipation/obviousness analysis)
• final disposition and instructions on remand

When does exclusivity end, and how does 14-1107 affect generic entry risk?

Featured answer: Exclusivity timing is driven by FDA exclusivity (marketing exclusivity, pediatric exclusivity) and patent expiration/listing in the Orange Book; 14-1107 can shift the effective entry date by sustaining or blocking patent-infringement findings.

Entry risk framework post-appeal

Once the patents and outcome are identified, the generic launch risk is assessed through:

• remaining unexpired patents that still block entry
• whether the ruling clears all asserted patents or only some
• settlement or consent-to-launch terms (if any)

Result: Without the case disposition and patent list, a launch-risk calculation cannot be stated.

Was there a Paragraph IV or consent-to-enter component in Takeda v. Impax 14-1107?

Featured answer: Many Takeda v. Impax disputes arise from a Paragraph IV ANDA challenge to Orange Book-listed patents.

What needs to be established for 14-1107

• Whether Impax filed a Paragraph IV certification (and to which patents)
• Whether there was an automatic stay
• Whether a settlement triggered a carve-out or launch date
• Whether any issues were dismissed for procedural reasons

Result: The factual record is not included, so the certification and stay timeline cannot be derived.

How strong is Takeda’s patent estate vs. Impax’s generic product in 14-1107?

Featured answer: Patent strength must be derived from the asserted claim set and the appellate outcome on validity and infringement.

Strength metrics used in litigation-grade assessments

Once asserted patents and holdings are known:

• survival rate of asserted claims
• breadth of construed claims vs. generic features
• whether validity arguments were decided on legal or factual grounds
• whether prior art mappings were accepted for obviousness/anticipation

Result: Without the asserted patents and holdings, strength cannot be quantified.

What generic launch scenarios exist after Takeda v. Impax 14-1107?

A complete answer requires:

• the mandate and whether the case was remanded
• whether Takeda retained any live injunction threat
• whether any patents were dropped or narrowed

Scenarios to model once the disposition is known

• Cleared all asserted patents: typical path to launch if no other blocking patents exist
• Partially cleared: launch delayed until the remaining patents expire or a separate settlement occurs
• Reinforced blocking patents: generic entry remains stayed or enjoined

Result: No scenario analysis can be stated without the appellate outcome.

How does Takeda v. Impax 14-1107 compare with other Takeda generics patent disputes?

A comparative litigation analysis needs:

• similar asserted technologies and claim types
• similar Federal Circuit claim construction themes
• outcomes across the portfolio

Result: Comparable case selection and thematic comparison cannot be executed without knowing which drug/patents are in 14-1107.

---

Key Takeaways

• The case is an ANDA-related patent dispute styled Takeda Pharmaceutical Co v. Impax Laboratories, Inc., 14-1107.
• A complete litigation summary and analysis requires the asserted patent list and the Federal Circuit disposition.
• Without case-specific record content (district court, patents, and holding), no accurate infringement/validity conclusions, no expiration/entry impact, and no claim-level strength assessment can be produced.

FAQs

1. What standard does the Federal Circuit apply in Hatch-Waxman patent appeals involving ANDAs?
2. How do claim construction outcomes typically affect infringement analysis in generic ANDA litigation?
3. What is the role of doctrine of equivalents in Takeda vs. Impax style ANDA disputes?
4. How does an adverse appellate ruling alter the practical launch timing for a proposed generic?
5. How do Orange Book listings and Paragraph IV certifications interact with the litigation stay?

---

References

(No sources cited because the required case-specific content (asserted patents, district court docket, and Federal Circuit disposition) is not present in the prompt.)